Aspen Ends Potential Deal For European Business
Aspen has terminated discussions with a potential partner around a deal to help it to optimize its European pharmaceuticals business.
You may also be interested in...
Another regulatory approval for Mylan and Upjohn’s proposed combination into Viatris has been ticked off, with the Australian Competition and Consumer Commission saying it will not oppose the deal after Upjohn agreed to divestments to Aspen Pharmacare.
With Mylan continuing to count down the days until its merger with Pfizer’s Upjohn completes, the US firm has struck a deal to acquire Aspen Pharmacare’s thrombosis business in Europe, bolstering what is already a $4bn operation.
Disposing of its Nutritionals business allows Aspen to fully focus on pharmaceuticals, while the firm is looking to drive organic growth with an emphasis on its Emerging Markets division, optimizing its complex manufacturing capabilities and seeking collaborations in territories where it “lacks sufficient critical mass”. These are among the measures Aspen has identified as it outlines four priorities for the firm, as the group shifts from being a regional generics company to a global specialty business.